AEM vs ASTL

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 5/9, indicating borderline stability, and a missing Altman Z-Score, which raises uncertainty around solvency risk. The company is unprofitable across all margins—gross, operating, and net—while reporting negative revenue growth and deeply negative earnings surprises. Valuation metrics appear deceptively cheap with a Price/Book of 0.75 and Price/Sales of 0.22, but these are misleading given the firm's deteriorating fundamentals and lack of earnings power. Despite a 3.42% dividend yield, the poor earnings coverage and declining cash flows cast doubt on sustainability, especially with a technical trend scoring 0/100 indicating strong bearish momentum.